Press Releases Indivior Pharmaceuticals, Inc. London S.E.

Stocks

INDV

US45579U1097

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:04 2025-07-24 am EDT			5-day change	1st Jan Change
1,238.00 ^GBX	+1.56%		+5.27%	+20.90%

Jun. 10	Indivior Pharmaceuticals Insider Sold Shares Worth $1,357,200, According to a Recent SEC Filing	MT
May. 20	Indivior Pharmaceuticals Announces Findings From Real-World Evidence Studies on Monthly Injectable Buprenorphine	CI

Press Releases

May. 21	Indivior Pharmaceuticals - New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization	AQ
Apr. 30	Indivior Pharmaceuticals : FINAL Indivior Q1 2026 Press Release 2026.04.30	PU
Apr. 30	Indivior Pharmaceuticals : FINAL Indivior 1Q26 Financial Results Deck Site Version	PU
Apr. 30	Indivior Pharmaceuticals : FINAL Indivior Corporate Investor Deck April 27	PU
Apr. 27	Indivior Presents New Real-World Data at ASAM 2026 Annual Conference, Supporting Remission as a Treatment Outcome and Reinforcing the Clinical Benefits of Monthly Injectable Buprenorphine for Opioid Use Disorder	AQ
Apr. 01	Indivior Pharmaceuticals - New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities	AQ
Mar. 12	Indivior Pharmaceuticals - New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder	AQ
Feb. 26	Indivior Pharmaceuticals : FINAL Indivior Corporate Investor Deck	PU
Feb. 26	Indivior Pharmaceuticals : FINAL Press Release	PU
Feb. 26	Indivior Pharmaceuticals : FINAL Indivior Q4 Financial Results Deck	PU
Jan. 29	Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26??	AQ
Jan. 26	Indivior Announces Completion of Redomiciliation to the United States	GL
Jan. 08	Indivior : Financial Document	PU
Jan. 08	Indivior Provides Full-Year 2026 Financial Guidance and Business Update	GL
Dec. 22	Indivior Announces Inclusion in the S&P SmallCap 600® Index	PR
Dec. 17	New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations	PR
Nov. 20	Indivior Concludes Legacy U.S. Department of Justice Matter	PR
Nov. 19	Indivior to Participate in the Piper Sandler 37th Annual Healthcare Conference	PR
Nov. 18	Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine	AQ
Nov. 03	Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine	PR
25-10-30	Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance	PR
25-10-28	Indivior to Participate in the Stifel 2025 Healthcare Conference	PR
25-10-16	Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th	PR
25-10-15	Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment	PR
25-10-01	Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation	PR